Stockholders’ Equity

6 Months Ended

Jun. 30, 2025

Stockholders’ Equity [Abstract]

Stockholders’ equity

7. Stockholders’ equity

Warrants

As of June 30, 2025, the following table summarizes the status of our outstanding and exercisable warrants and related transactions since December 31, 2024 (in thousands, except weighted average exercise price and weighted average remaining contractual life data):

	Warrants outstanding and exercisable
	Warrants		Weighted Average Exercise Price		Aggregate Intrinsic Value		Weighted Average Remaining Contractual Life (in Years)
As of December 31, 2024		98	$	63.33		-		5.6
As of June 30, 2025		98	$	63.33	$	-		5.1

Share-based compensation payment plans

As of June 30, 2025, 51,030 shares of common stock were subject to outstanding awards under our share-based payment award plans and inducement grants (calculated using the base number of PSUs that may vest). As of June 30, 2025, 416,219 shares of common stock were available for future grants of share-based payment awards under the TherapeuticsMD, Inc. 2019 Stock Incentive Plan.

The following table summarizes the status of our outstanding and exercisable options and related transactions since December 31, 2024 (in thousands, except weighted average exercise price and weighted average remaining contractual life data):

	Outstanding									Exercisable
	Options Awards			Weighted Average Exercise Price		Aggregate Intrinsic Value		Weighted Average Remaining Contractual Life (in Years)		Options Awards			Weighted Average Exercise Price		Aggregate Intrinsic Value		Weighted Average Remaining Contractual Life (in Years)
As of December 31, 2024		57		$	270.33	$	—		2.8		57		$	270.20	$	—		2.8
Expired		(6	)		312.36		—		—		(6	)		—		—		—
As of June 30, 2025		51		$	265.80	$	—		2.5		51		$	265.66	$	—		2.5

The following table summarizes the status of our RSUs and related transactions since December 31, 2024 (in thousands, except weighted average grant date fair value):

	RSUs awards outstanding
	RSUs			Weighted Average Grant Date Fair Value		Aggregate Intrinsic Value
Balance, as of December 31, 2024		2		$	21.78	$	1.50
Vested		(2	)		21.78		—
Balance, as of June 30, 2025		—		$	—	$	—

The following table summarizes the status of our PSUs and related transactions since December 31, 2024 (in thousands, except weighted average grant date fair value):

	PSUs			Weighted Average Grant Date Fair Value		Aggregate Intrinsic Value
Unvested, as of December 31, 2024		5		$	34.50	$	4.47
Vested		(5	)		34.50		—
Balance, as of June 30, 2025		—		$	—	$	—

Share-based payment compensation cost

Share-based payment compensation expense for PSUs is based on 100% vesting which was a part of the termination benefits for all employees who were terminated in 2022. We recorded share-based payment award compensation costs related to previously issued options, RSU and PSUs, as well as shares of common stock issued under our employee stock purchase plan (“ESPP”) totaling $1 thousand and $96 thousand for the three months ended June 30, 2025 and 2024, respectively, and $24 thousand and $207 thousand for the six months ended June 30, 2025 and 2024, respectively.

As of June 30, 2025, there was no unrecognized share-based payment award compensation cost related to unvested options, RSUs and PSUs as well as shares issuable under our ESPP. No tax benefit was realized due to a continued pattern of net losses.